Seminars in Pediatric Surgery
Volume 15, Issue 1 , Pages 57-62 , February 2006

Childhood rhabdomyosarcoma

  • David Rodeberg, MD

      Affiliations

    • Department of Pediatric Surgery, Children’s Hospital of Pittsburgh, Pittsburgh, Pennsylvania
    • ,
  • Charles Paidas, MD, MBA

      Affiliations

    • Department of Surgery, Division of Pediatric Surgery, University of South Florida, Tampa, Florida
    • Corresponding Author InformationAddress reprint requests and correspondence: Charles Paidas, MD, MBA, Tampa General Hospital, Pediatric Surgery, Rm. G-441, PO Box 1289, Tampa, FL 33601

References 

  1. Crist WM , Garnsey L , Beltangady MS , et al.   Prognosis in children with rhabdomyosarcoma: a report of the intergroup rhabdomyosarcoma studies I and II. Intergroup Rhabdomyosarcoma Committee . J Clin Oncol . 1990;8:443–452
  2. Spunt SL , Lobe TE , Pappo AS , et al.   Aggressive surgery is unwarranted for biliary tract rhabdomyosarcoma . J Pediatr Surg . 2000;35:309–316
  3. Crist WM , Anderson JR , Meza JL , et al.   Intergroup rhabdomyosarcoma study-IV (results for patients with nonmetastatic disease) . J Clin Oncol . 2001;19:3091–3102
  4. Parham DM . Pathologic classification of rhabdomyosarcomas and correlations with molecular studies . Mod Pathol . 2001;14:506–514
  5. Scrable H , Witte D , Shimada H , et al.   Molecular differential pathology of rhabdomyosarcoma . Genes Chromosomes Cancer . 1989;1:23–35
  6. Gordon T , McManus A , Anderson J , et al.   Cytogenetic abnormalities in 42 rhabdomyosarcoma (a United Kingdom Cancer Cytogenetics Group Study) . Med Pediatr Oncol . 2001;36:259–267
  7. De Zen L , Sommaggio A , d’Amore ES , et al.   Clinical relevance of DNA ploidy and proliferative activity in childhood rhabdomyosarcoma (a retrospective analysis of patients enrolled onto the Italian Cooperative Rhabdomyosarcoma Study RMS88) . J Clin Oncol . 1997;15:1198–1205
  8. Barr FG . Molecular genetics and pathogenesis of rhabdomyosarcoma . J Pediatr Hematol Oncol . 1997;19:483–491
  9. Merlino G , Helman LJ . Rhabdomyosarcoma (working out the pathways) . Oncogene . 1999;18:5340–5348
  10. Bortolozzi S , Bisognin A , Romualdi C , et al.   Novel genes, possibly relevant for molecular diagnosis or therapy of human rhabdomyosarcoma, detected by genomic expression profiling . Gene . 2005;348:65–71
  11. Schofield D , Triche TJ . eDNA microarray analysis of global gene expression in sarcomas . Curr Opin Oncol . 2002;14:406–411
  12. Leuscher I , Langhans I , Schmitz R , et al.   p53 and mdm-2 expression in Rhabdomyosarcoma of childhood and adolescence (clinicopathologic study by the Kiel Pediatric Tumor Registry and the German Cooperative Soft Tissue Sarcoma Study) . Pediatr Dev Pathol . 2003;6:128–135
  13. Scotland K , Manara MC , Nicoletti G , et al.   Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors . Cancer Res . 2005;65:3868–3876
  14. Dickens DS , Cripe TP . Effect of combined cyclooxygenase-2 and matrix metalloproteinase inhibition on human sarcoma xenografts . J Pediatr Hematol Oncol . 2003;25:709–714
  15. Williamson D , Lu YJ , Gordon T , et al.   Relationship between MYCN copy number and expression in rhabdomyosarcoma and correlation with adverse prognosis in the alveolar subtype . J Clin Oncol . 2005;23:880–888
  16. Hays DM , Lawrence W , Wharam M , et al.   Primary reexcision for patients with “microscopic residual” tumor following initial excision of sarcomas of trunk and extremity sites . J Pediatr Surg . 1989;24:5–10
  17. Neville HL , Andrassy RJ , Lobe TE , et al.   Preoperative staging, prognostic factors, and outcome for extremity rhabdomyosarcoma (a preliminary report from the Intergroup Rhabdomyosarcoma Study IV (1991-1997)) . J Pediatr Surg . 2000;35:317–321
  18. Wiener ES , Anderson JR , Ojimba JI , et al.   Controversies in the management of paratesticular rhabdomyosarcoma (is staging retroperitoneal lymph node dissection necessary for adolescents with resected paratesticular rhabdomyosarcoma?) . Semin Pediatr Surg . 2001;10:146–152
  19. Rodeberg DA , Paidas CN , Lobe TT , et al.   Surgical Principles for children adolescents with newly diagnosed rhabdomyosarcoma (a report from the Soft Tissue Sarcoma Committee of the Children’s Oncology Group) . Sarcoma . 2002;6:111–122
  20. Wiener E . Second look operations in children in group III and IV, rhabdomyosarcoma . Med Pediatr Oncol . 1990;18:408
  21. Wiener E , Lawrence W , Hays D , et al.   Complete response or not complete response? Second look operations are the answer in children with rhabdomyosarcoma . Proc Am Soc Clin Oncol . 1991;10:316
  22. La Quaglia MP . The surgical management of metastases in pediatric cancer . Semin Pediatr Surg . 1993;2:75–82
  23. Rodeberg D , Arndt C , Breneman J , et al.   Characteristics and outcomes of rhabdomyosarcoma patients with isolated lung metastases from IRS-IV . J Pediatr Surg . 2005;40:256–262
  24. Arndt CA , Crist WM . Common musculoskeletal tumors of childhood and adolescence . N Engl J Med . 1999;341:342–352
  25. Pappo AS , Anderson JR , Crist WM , et al.   Survival after relapse in children and adolescents with rhabdomyosarcoma (a report from the Intergroup Rhabdomyosarcoma Study Group) . J Clin Oncol . 1999;17:3487–3493
  26. Mandell LR . Ongoing progress in the treatment of childhood rhabdomyosarcoma . Oncology . 1993;7:71–83 discussion 84-6, 89-90.
  27. Raney RB , Anderson JR , Barr FG , et al.   Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life (a selective review of intergroup rhabdomyosarcoma study group experience and rationale for Intergroup Rhabdomyosarcoma Study V) . J Pediatr Hematol Oncol . 2001;23:215–220
  28. Breneman J , Anderson J , Donaldson S , et al.   Prognostic factors and outcome in children with metastatic rhabdomyosarcoma (a report from the Intergroup Rhabdomyosarcoma Study IV) . Int J Radiat Oncol Biol Phys . 2001;51(suppl 1):118; A-210, [Abstract]
  29. Crist WM , Garnsey L , Beltangady MS , et al.   Prognosis in children with rhabdomyosarcoma: a report of the intergroup rhabdomyosarcoma studies I and II. Intergroup Rhabdomyosarcoma Committee . J Clin Oncol . 1990;8:443–452
  30. Pappo AS , Etcubanas E , Santana VM , et al.   A phase II trial of ifosfamide in previously untreated children and adolescents with unresectable rhabdomyosarcoma . Cancer . 1993;71:2119–2125
  31. Baker KS , Anderson JR , Link MP , et al.   Benefit of intensified therapy for patients with local or regional embryonal rhabdomyosarcoma (results from the Intergroup Rhabdomyosarcoma Study IV) . J Clin Oncol . 2000;18:2427–2434
  32. Spunt SL , Smith LM , Ruymann FB , et al.   Cyclophosphamide dose intensification during induction therapy for intermediate-risk pediatric rhabdomyosarcoma is feasible but does not improve outcome (a report from the soft tissue sarcoma committee of the children’s oncology group) . Clin Cancer Res . 2004;10:6072–6079
  33. Breitfeld PP , Lyden E , Raney RB , et al.   Ifosfamide and etoposide are superior to vincristine and melphalan for pediatric metastatic rhabdomyosarcoma when administered with irradiation and combination chemotherapy (a report from the Intergroup Rhabdomyosarcoma Study Group) . J Pediatr Hematol Oncol . 2001;23:225–233
  34. Sandler E , Lyden E , Ruymann F , et al.   Efficacy of ifosfamide and doxorubicin given as a phase II “window” in children with newly diagnosed metastatic rhabdomyosarcoma (a report from the Intergroup Rhabdomyosarcoma Study Group) . Med Pediatr Oncol . 2001;37:442–448
  35. Breneman JC , Lyden E , Pappo AS , et al.   Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma (a report from the Intergroup Rhabdomyosarcoma Study IV) . J Clin Oncol . 2003;21:78–84
  36. Pappo AS , Lyden E , Breneman J , et al.   Up-front window trial of topotecan in previously untreated children and adolescents with metastatic rhabdomyosarcoma (an intergroup rhabdomyosarcoma study) . J Clin Oncol . 2001;19:213–219
  37. Walterhouse DO , Lyden ER , Breitfeld PP , et al.   Efficacy of topotecan and cyclophosphamide given in a phase II window trial in children with newly diagnosed metastatic rhabdomyosarcoma (a Children’s Oncology Group study) . J Clin Oncol . 2004;22:1398–1403
  38. Maurer HM , Gehan EA , Beltangady M , et al.   The Intergroup Rhabdomyosarcoma Study-II . Cancer . 1993;71:1904–1922
  39. Wolden SL , Anderson JR , Crist WM , et al.   Indications for radiotherapy and chemotherapy after complete resection in rhabdomyosarcoma (a report from the Intergroup Rhabdomyosarcoma Studies I to III) . J Clin Oncol . 1999;17:3468–3475
  40. Mandell L , Ghavimi F , Peretz T , et al.   Radiocurability of microscopic disease in childhood rhabdomyosarcoma with radiation doses less than 4,000 cGy . J Clin Oncol . 1990;8:1536–1542
  41. Donaldson SS , Meza J , Anderson JR , et al.   Results from the IRS-IV randomized trial of hyperfractionated radiotherapy in children with rhabdomyosarcoma (a report from the IRSG) . Int J Radiat Oncol Biol Phys . 2001;51:718–728
  42. Lawrence W , Anderson JR , Gehan EA , et al.  Children’s Cancer Study Group   Pretreatment TNM staging of childhood rhabdomyosarcoma (a report of the Intergroup Rhabdomyosarcoma Study Group) . Pediatric Oncology Group Cancer . 1997;80:1165–1170

PII: S1055-8586(05)00094-6

doi: 10.1053/j.sempedsurg.2005.11.009

Seminars in Pediatric Surgery
Volume 15, Issue 1 , Pages 57-62 , February 2006

Article Tools